3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lymphoma
8
Lymphoma, Follicular
7
Leukemia
7
Prostatic Neoplasms
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Glioblastoma
3
Burkitt Lymphoma
3
Astrocytoma
3
Stomach Neoplasms
2
Rectal Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Chronic-Phase
2
Colonic Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Interventions
sargramostim
1
Temozolomide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Tetanus
×
sargramostim
×
Clear all
NCT03927222
2024-04-08
I-ATTAC
Duke University
Phase 2
Terminated
6 enrolled
7 charts